Uptake of 2-1-1 Dosing of Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) as an Alternative to Daily PrEP at a Sexual Health Clinic in San Francisco

被引：0
|
作者：
Bacon, Oliver [1 ]
Sankaran, Madeline [2 ]
Levy, Montica [1 ]
Kohn, Robert P. [2 ]
Cohen, Stephanie E. [1 ]
机构：
[1] San Francisco Dept Publ Hlth, San Francisco City Clin, San Francisco, CA USA
[2] San Francisco Dept Publ Hlth, San Francisco, CA USA
来源：
SEXUALLY TRANSMITTED DISEASES | 2022年 / 49卷 / 10S期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 12 条
  • [1] PrEP 2-1-1 education increases PrEP uptake and preserves effective PrEP coverage in a large nurse-led community-based sexual health clinic in San Francisco
    Broussard, J.
    Bena, J.
    Crouch, P. -C.
    Taylor, B.
    Chavez, M.
    Grant, R. M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 42 - 43
  • [2] Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent
    Post, Frank
    Yazdanpanah, Yazdan
    Schembri, Gabriel
    Lazzarin, Adriano
    Reynes, Jacques
    Maggiolo, Franco
    Yan, Mingjin
    Abram, Michael
    Tran-Muchowski, Cecilia
    Cheng, Andrew
    Rhee, Martin
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [3] COST-EFFECTIVENESS OF EVERY TWO MONTH CABOTEGRAVIR LONG-ACTING (CAB-LA) FOR PRE-EXPOSURE PROPHYLAXIS (PREP) COMPARED WITH DAILY ORAL TENOFOVIR DISOPROXIL FUMARATE (TDF)/ EMTRICITABINE (FTC) AS PREP TO PREVENT HIV-1 IN THE UK
    O'Brien, P.
    Campbell, K.
    Anderson, S. J.
    Cornic, L.
    Davis, A.
    Schroeder, M.
    VALUE IN HEALTH, 2024, 27 (06) : S109 - S109
  • [4] Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial
    Post, Frank A.
    Yazdanpanah, Yazdan
    Schembri, Gabriel
    Lazzarin, Adriano
    Reynes, Jacques
    Maggiolo, Franco
    Yan, Mingjin
    Abram, Michael E.
    Tran-Muchowski, Cecilia
    Cheng, Andrew
    Rhee, Martin S.
    HIV CLINICAL TRIALS, 2017, 18 (03): : 135 - 140
  • [5] Lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) provides more rapid viral decline than LPV/r combined with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment HIV-1-infected subjects
    Podsadecki, T.
    Tian, M.
    Fredrick, L.
    Lawal, A.
    Bernstein, B.
    HIV MEDICINE, 2009, 10 : 19 - 20
  • [6] Tolerance and viral resistance after single-dose nevirapine (NVP) and short-course of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) to prevent mother-to-child transmission (PMTCT) of HIV-1: the TEmAA ANRS 12109 phase II trial, step 1
    Elise Arrivé
    Stéphane Blanche
    Marie-Laure Chaix
    Eric Nerrienet
    Christine Rouzioux
    James McIntyre
    Glenda Gray
    Patrick Coffie
    Kruy Leang Sim
    Didier Ekouévi
    François Dabis
    Retrovirology, 5 (Suppl 1)
  • [7] Assessments of very low level HIV replication for dolutegravir plus lamivudine (DTG+3TC) vs dolutegravir plus tenofovir disoproxil/emtricitabine (DTG plus TDF/FTC) in the GEMINI 1&2 studies through week 96
    Underwood, M.
    Urbaityte, R.
    Wang, R.
    Tenorio, A.
    Wynne, B.
    Pappa, K.
    Koteff, J.
    Gartland, M.
    Van Wyk, J.
    Man, C.
    Sievers, J.
    HIV MEDICINE, 2019, 20 : 23 - 23
  • [8] Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults
    Orkin, C.
    Molina, J-M
    Gallant, J.
    Negredo, E.
    Gathe, J.
    Eron, J.
    van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Petrovic, R.
    Opsomer, M.
    HIV MEDICINE, 2018, 19 : S32 - S32
  • [9] Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatmentnai naive women with HIV-1 infection (ARIA Study)
    Orrell, C.
    Hagins, D.
    Belonosova, E.
    Porteiro, N.
    Walmsley, S.
    Falco, V.
    Man, C.
    Aylott, A.
    Buchanan, A.
    Wynne, B.
    Vavro, C.
    Aboud, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [10] Week-48 results of AMBER: phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
    Gallant, J.
    Orkin, C.
    Molina, J-M
    Negredo, E.
    Antinori, A.
    Mills, A.
    Eron, J.
    Reynes, J.
    van Landuyt, E.
    Hufkens, V.
    Jezorwski, J.
    Opsomer, M.
    HIV MEDICINE, 2018, 19 : S32 - S32
12